Literature DB >> 10837755

Vaccine delivery to animals.

.   

Abstract

For many years vaccination of animals has been practiced to prevent infectious diseases using inactivated organisms or modified live organisms. The live vaccines were effective but lacked safety. The vaccines made with inactivated organisms required an adjuvant to induce an immune response that was not as effective as either the clinical disease or live vaccines. An 'ideal' vaccine would induce effective immunity specific for the type of infection, have long duration, require minimal or no boosters, have impeccable safety, would not induce adverse reactions, and be easy to administer. The desire to meet these criteria, and especially safety, has resulted in the development of vaccines that do not depend on the use of the viable disease agent. The emphasis on subunit or inactivated vaccines that meet the desired criteria of a perfect vaccine has resulted in a critical need for better adjuvants and delivery systems. This has resulted in a technological innovation revolution with development of a wide array of different technologies to generate effective vaccines. This review will describe the historical relevance of adjuvants used for parenterally administered inactivated/subunit vaccines as well as describe some of the exciting technological advances including adjuvants (ISCOMS), delivery systems (recombinant vectors, microparticles), and novel approaches (transgenic plants, naked DNA) that are currently being, or will be used in the future, in the search for better, more effective vaccines that meet the current and future needs of veterinary medicine.

Entities:  

Year:  1999        PMID: 10837755     DOI: 10.1016/s0169-409x(99)00015-0

Source DB:  PubMed          Journal:  Adv Drug Deliv Rev        ISSN: 0169-409X            Impact factor:   15.470


  14 in total

1.  Bursopentine as a novel immunoadjuvant enhances both humoral and cell-mediated immune responses to inactivated H9N2 Avian Influenza virus in chickens.

Authors:  Deyuan Li; Maoyun Xue; Chen Wang; Junbao Wang; Puyan Chen
Journal:  Clin Vaccine Immunol       Date:  2011-07-27

Review 2.  Adjuvant effects of saponins on animal immune responses.

Authors:  Zahid Iqbal Rajput; Song-hua Hu; Chen-wen Xiao; Abdullah G Arijo
Journal:  J Zhejiang Univ Sci B       Date:  2007-03       Impact factor: 3.066

3.  Effects of Selected Adjuvants on Immunogenicity and Protectivity of Pasteurella multocida Bacterin Vaccine in Chickens.

Authors:  R Ghadimipour; M Ghorbanpoor; D Gharibi; M Mayahi; A R Jabbary
Journal:  Arch Razi Inst       Date:  2021-10-31

4.  Evolving importance of biologics and novel delivery systems in the face of microbial resistance.

Authors:  Terry L Bowersock
Journal:  AAPS PharmSci       Date:  2002

Review 5.  Vaccine adjuvants: current challenges and future approaches.

Authors:  Jennifer H Wilson-Welder; Maria P Torres; Matt J Kipper; Surya K Mallapragada; Michael J Wannemuehler; Balaji Narasimhan
Journal:  J Pharm Sci       Date:  2009-04       Impact factor: 3.534

6.  Effect of alum co-adjuvantation of oil adjuvant vaccine on emulsion stability and immune responses against haemorhagic septicaemia in mice.

Authors:  Sujeet Kumar; Vinod Kumar Chaturvedi; Bablu Kumar; Pankaj Kumar; Sudha Rani Somarajan; Anil Kumar Mishra; Bhaskar Sharma
Journal:  Iran J Microbiol       Date:  2015-04

7.  In ovo vaccination using Eimeria profilin and Clostridium perfringens NetB proteins in Montanide IMS adjuvant increases protective immunity against experimentally-induced necrotic enteritis.

Authors:  Hyun Soon Lillehoj; Seung Ik Jang; Alfredo Panebra; Erik Peter Lillehoj; Laurent Dupuis; Juliette Ben Arous; Seung Kyoo Lee; Sung Taek Oh
Journal:  Asian-Australas J Anim Sci       Date:  2017-03-21       Impact factor: 2.509

8.  Evaluation of Montanide™ ISA 71 VG adjuvant during profilin vaccination against experimental coccidiosis.

Authors:  Seung I Jang; Duk Kyung Kim; Hyun S Lillehoj; Sung Hyen Lee; Kyung Woo Lee; François Bertrand; Laurent Dupuis; Sébastien Deville; Juliette Ben Arous; Erik P Lillehoj
Journal:  PLoS One       Date:  2013-04-08       Impact factor: 3.240

9.  A recombinant chimera comprising the R1 and R2 repeat regions of M. hyopneumoniae P97 and the N-terminal region of A. pleuropneumoniae ApxIII elicits immune responses.

Authors:  Seung Heon Lee; Seungwoo Lee; Chanhee Chae; Doug-Young Ryu
Journal:  BMC Vet Res       Date:  2014-02-18       Impact factor: 2.741

10.  Identification of Molecular Signatures from Different Vaccine Adjuvants in Chicken by Integrative Analysis of Microarray Data.

Authors:  Duk Kyung Kim; Kyeong Hye Won; Seung Hyun Moon; Hak-Kyo Lee
Journal:  Asian-Australas J Anim Sci       Date:  2015-04-06       Impact factor: 2.509

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.